ArticleMetabolic brain disease2025
Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Inflammatory models of depression in rodents and humans.Frontiers in psychiatry · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ayahuasca (Aya) is an Amazonian beverage traditionally used as medicine by Indigenous people in South America to treat various illnesses and have shown a potential to treat depression. This study aimed to investigate the antidepressant effects of fluoxetine, Aya and N, N dimethyl tryptamine (DMT), a component of the beverage, focusing on the modulation of inflammatory serum cytokine profiles and behavior of Wistar rats subjected to lipopolysaccharide (LPS)-induced depression. In total, 126 rats were randomly assigned to seven groups: saline control, LPS, fluoxetine, three ayahuasca groups (dosed at 0.5, 1, and 2 times the usual ritualistic dose, Aya0.5, Aya1 and Aya2), and one DMT treatment group. The rats received LPS every other day from day 1 to 13 and fluoxetine, Aya and DMT daily from day 2 to 14. At day 15, the rats were submitted to open field and forced swimming tests, plasma samples were collected and the animals were euthanized. The LPS group showed lower body weight grain and higher plasma levels of pro-inflammatory cytokines IL-1α (p < 0.001), TNF-α, and IL-12p70 compared to control, which were significantly reduced by the treatment groups (p < 0.05 up to p < 0.0001), indicating a potential for modulation of the inflammatory state seen in depression. The Aya2 group exhibited increased locomotion in the open field arena compared to the fluoxetine (p < 0.05) and DMT (p < 0.01) groups, with a significantly higher percentage of entries into the center than the control group (p < 0.01). Furthermore, treatments with fluoxetine, Aya, and DMT significantly increased swimming time compared to the LPS group (p < 0.01), and fluoxetine and the Aya0.5 groups displayed higher climbing times compared to LPS and control (p < 0.05). Although the LPS model did not consistently induce depressive-like behaviors, the results highlight the potential of ayahuasca and DMT to modulate the immune system and reduce pro-inflammatory cytokine levels associated with depression, which could have significant implications for treating inflammation-related aspects of depression.
Indexed as
Identifiers
40498206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.